Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
4 Drug Stocks that are Broker Favorites
by Arpita Dutt
Here's a look at 4 drug stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies.
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
by Arpita Dutt
Major highlights this week were earnings results from companies like Celgene (CELG) and pipeline updates.
The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals
4 FDA Decisions to Watch Out for in Feb 2017
by Arpita Dutt
So far this year, the FDA has approved one drug. Will the pace of drug approvals pick up in February?
Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid
by Zacks Equity Research
Celgene Corporation (CELG) announced that the EMA's CHMP has rendered a positive opinion for oncology drug Revlimid as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma.
Celgene (CELG) Misses on Earnings & Revenues, Keeps View
by Zacks Equity Research
Celgene (CELG) reported fourth-quarter 2016 earnings of $1.41 per share (including share-based compensation expense and tax adjustments), missing the Zacks Consensus Estimate of $1.43.
Celgene (CELG) Misses On Q4 Earnings & Revenues
by Ekta Bagri
Celgene Corporation (CELG) missed on both earnings and revenues in Q4.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY
by Zacks Equity Research
How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?
Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review
by Arpita Dutt
There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.
Prima Biomed Initiates Randomized Study for Breast Cancer
by Zacks Equity Research
Prima (PBMD) dosed the first patient in the enlarged randomized phase of the phase IIb study -- AIPAC -- on IMP321 for the treatment of metastatic breast cancer.
Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.
4 Top Biotech Mutual Funds for 2017
by Zacks Equity Research
Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance
Medidata Solutions Clinical Cloud Gets Picked by Celgene
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced that Celgene Corporation adopted Medidata Clinical Cloud.
Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short
by Arpita Dutt
Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.
Celgene Issues Preliminary 2016 Results, Lifts 2017 View
by Zacks Equity Research
Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.
Halozyme (HALO) Up on Positive Phase II Data on PEGPH20
by Zacks Equity Research
Halozyme (HALO) announced top-line data from the combined analysis from its phase II HALO 202 study on PEGPH20.
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
by Zacks Equity Research
Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.
Prima (PBMD) Reports Favorable Initial Melanoma Study Data
by Zacks Equity Research
Prima (PBMD) announced interim data from the TACTI-mel program on IMP321 for the treatment of patients with unresectable or metastatic melanoma.
The Zacks Analyst Blog Highlights: Celgene, 21st Century Fox, Prudential, Amazon and Exelon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, 21st Century Fox, Prudential, Amazon and Exelon
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold
by Arpita Dutt
Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.
Top Research Reports for December 28, 2016
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), 21st Century Fox (FOXA) and Prudential (PRU).
Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead
by Arpita Dutt
We advise investors to focus on biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.